Start with the outcome, population or study design you care about. Every result keeps its released bottom line and its boundary together.
Side-by-side view
Compare up to three released stories
Keep population, design, measured outcome and interpretation boundaries together. Adjacency and order are not evidence strength, efficacy, safety, equivalence, importance, popularity or recommendation.
No stories selected
Select a story below to begin. A second selection creates the side-by-side view.
Three-story limit reached. Remove one story before choosing another.
No exact match
No released story matches all five choices.
Clear one filter to widen the view. The tracker never invents a result to fill an empty combination.
Primary outcome group
Function & independence
What changed in mobility, sleep, strength, bone density, or day-to-day function?
16 stories
Story and measured outcomesPopulation and designBottom lineBoundary and date
Measurement methods · Instrument-specific physical components, selected health deficits and performance tasks; observational prognostic associations
Human measurement methods · historical observational validation, with consensus and molecular context
Population or modelThree separate historical older-adult cohorts: Fried 5,317 aged 65+; Searle 754 aged 70+ with 681 at follow-up; Guralnik 5,174 selected home-living respondents aged 71+ with task-specific denominators. No pooling.
Methods explainer comparing physical phenotype, deficit accumulation and performance inputs; no intervention comparison or score conversion
Released bottom line
The instruments use different inputs and protocols. These core observational validations do not by themselves establish that treatment-induced score changes extend lifespan.
What this does not establish
No individual diagnosis, best-tool ranking, score conversion, treatment recommendation or proof that a changed score reverses aging or adds healthy years.
Source status checked
low-methoxy citrus pectin · paper-defined inflammatory markers plus secondary physical-function and psychological measures
Human frailty/pre-frailty · small randomized four-week nutrition pilot
Population or model31 adults older than 65 with frailty or pre-frailty randomized at one Nottingham centre; 29 completed; most were pre-frail
blinded parallel randomized pilot; 10 g/day low-methoxy citrus pectin plus whey/cocoa versus matched whey/cocoa without pectin for four weeks
Released bottom line
The paper-defined TNF-α, IFN-γ and zonulin outcomes showed no significant between-group change; secondary physical, psychological and exploratory microbiome signals require replication.
What this does not establish
The pilot did not establish treatment or reversal of frailty, a causal microbiome mechanism, broad safety, durable function, disease prevention, healthspan, lifespan or supplement advice.
Source status checked
exercise, multidomain programs, supplements and caloric restriction · multidimensional function and well-being
Human multidimensional function and well-being · systematic review of randomized trials
Population or model4,656 participants across 15 unique randomized studies, mostly older adults in high- or upper-middle-income settings
registered systematic review with qualitative synthesis; study-specific randomized comparators
Released bottom line
The review described small, heterogeneous study-level signals but produced no pooled effect estimate or evidence of added healthy years.
What this does not establish
The review did not establish a treatment ranking, benefit from every exercise program, class-wide supplement or caloric-restriction benefit, disease prevention, mortality benefit or lifespan extension.
Checked
nurse-led multifactorial fall-injury prevention · time to first adjudicated serious fall injury
Human function and biomarkers · small randomized trial
Population or modelSelected older adults with lower mitochondrial function
small randomized trial
Released bottom line
ENERGIZE found no significant benefit for six-minute walk distance or maximal ATP production. Secondary endurance and biomarker signals remain preliminary and do not establish disability prevention or longer healthy life.
What this does not establish
Urolithin A missed both primary outcomes in older adults
Checked
low-dose aspirin · disability-free survival · major bleeding
Human function and safety · large randomized trial
Population or model19,114 community-dwelling older adults without cardiovascular disease, dementia or independence-limiting disability at enrollment
large randomized trial
Released bottom line
In 19,114 selected older adults, daily low-dose aspirin did not improve the trial’s composite of death, dementia or persistent physical disability over a median 4.7 years. Major hemorrhage was higher.
What this does not establish
ASPREE found no gain in disability-free survival—and more major bleeding
Checked
testosterone · six-minute walking distance and a 50-meter improvement threshold
Human physical-function outcomes · one-year randomized trials
Population or model790 symptomatic men age 65 or older with repeatedly low testosterone; 390 enrolled in the Physical Function Trial
one-year randomized trials
Released bottom line
The prespecified Physical Function Trial threshold was not significant in its enrolled subgroup; broader secondary walking results do not establish disability prevention, healthspan or longevity.
What this does not establish
Testosterone’s walking result was modest—not an anti-aging effect
Checked
CBT-I · sleep latency, sleep efficiency, insomnia remission and durability
Human BMD and function · small supervised randomized trial
Population or model101 screened postmenopausal women with low bone mass; mean age 65
small supervised randomized trial
Released bottom line
LIFTMOR found BMD and function gains in a small, screened, closely supervised trial—not fracture prevention or proof that unsupervised heavy training is safe.
What this does not establish
LIFTMOR improved bone density in a small supervised trial—not fracture prevention
Checked
creatine · lean tissue, strength and bone or muscle imaging
Human clinical outcomes · methods explainer using two randomized trials
Population or modelSPRINT’s 9,361 higher-risk adults without diabetes or prior stroke and ASPREE’s 19,114 selected older primary-prevention adults
methods explainer using two large randomized trials; outcomes and scales kept separate
Released bottom line
Relative and absolute effects answer different questions; both require the two group rates, denominator, outcome, follow-up and uncertainty.
What this does not establish
The explainer does not estimate an individual’s risk, rank treatments, convert hazard ratios into cumulative risk, or recommend a medication or blood-pressure target.
Checked
intensive lifestyle or metformin for diabetes prevention · cumulative type 2 diabetes incidence and aggregate microvascular disease
Human diabetes incidence and microvascular outcomes · long randomized follow-up
Population or model2,776 surviving DPP participants with elevated glucose and overweight or obesity who joined long-term follow-up
randomized lifestyle or metformin versus placebo, followed observationally after the original trial
Released bottom line
Over 15 years, cumulative diabetes incidence was 55% with intensive lifestyle, 56% with metformin and 62% with placebo. The randomized groups did not differ significantly in aggregate microvascular prevalence.
What this does not establish
The follow-up did not demonstrate that either randomized assignment reduced the aggregate microvascular outcome or extended life.
Checked
intensive lifestyle intervention for weight loss and physical activity · major cardiovascular events, weight and cardiometabolic risk factors
Human cardiovascular events and function · large randomized trial
Population or model5,145 adults age 45–75 with type 2 diabetes and overweight or obesity
intensive lifestyle intervention versus diabetes support and education
Released bottom line
The primary cardiovascular outcome occurred in 403 intensive-lifestyle participants and 418 controls (hazard ratio 0.95; P=0.51). Weight loss and several risk factors improved more with intensive lifestyle.
What this does not establish
Look AHEAD did not establish that its intensive lifestyle program reduced major cardiovascular events or extended life in this population.
Checked
low-dose aspirin · cardiovascular events · major bleeding
Human cardiovascular and safety outcomes · large randomized trial
Population or model19,114 community-dwelling older adults without cardiovascular disease at enrollment
large randomized trial
Released bottom line
In selected older adults without cardiovascular disease, low-dose aspirin did not significantly reduce the trial’s cardiovascular composite. Major hemorrhage occurred more often.
What this does not establish
ASPREE did not lower cardiovascular events—and increased major bleeding
Checked
testosterone · major cardiovascular events and cardiovascular safety outcomes
Human cardiovascular outcomes · large randomized noninferiority trial
Population or model5,246 men age 45–80 with symptoms, repeatedly low testosterone and preexisting or high cardiovascular risk
large randomized noninferiority trial
Released bottom line
Among selected men with hypogonadism and elevated cardiovascular risk, testosterone gel was noninferior to placebo for major cardiovascular events; the trial did not test longer life or general anti-aging use.
What this does not establish
TRAVERSE found cardiovascular noninferiority—not a longevity benefit
Checked
testosterone · clinical fractures and bone-density measures
Human fracture and bone-density outcomes · randomized trials
Population or model5,204 TRAVERSE participants: middle-aged and older men with symptoms, repeatedly low testosterone and preexisting or high cardiovascular risk
randomized trials
Released bottom line
Clinical fractures were more frequent with testosterone than placebo in TRAVERSE; a smaller substudy’s bone-density gain cannot substitute for fracture outcomes.
What this does not establish
Testosterone did not prevent fractures in TRAVERSE
Checked
CPAP · major cardiovascular events, sleepiness, symptoms and quality of life
Population or model7,765 postmenopausal women with osteoporosis; mean age about 73
large randomized trial
Released bottom line
HORIZON reduced vertebral and hip fractures in postmenopausal osteoporosis, with outcome-specific duration and safety limits—not evidence of slower aging.
What this does not establish
Zoledronic acid reduced fractures in osteoporosis—not aging itself
Checked
vitamin D · invasive cancer, major cardiovascular events and clinical fractures
Human clinical outcomes · large randomized prevention trial
Population or model25,871 generally healthy U.S. adults not selected for vitamin D deficiency, low bone mass or osteoporosis
large randomized prevention trial
Released bottom line
In generally healthy adults, vitamin D3 did not significantly reduce invasive cancer, major cardiovascular events, or fractures; deficiency treatment is a different question.
What this does not establish
Vitamin D is essential. VITAL still found no broad prevention benefit
Population or model9,361 adults age 50 or older at elevated cardiovascular risk, without diabetes or prior stroke
large randomized trial
Released bottom line
Intensive treatment lowered cardiovascular events and mortality in eligible high-risk adults, with more hypotension, electrolyte problems and kidney injury.
Human clinical outcomes · formulation-specific randomized trials
Population or modelPrimary-prevention adults, older adults after myocardial infarction and statin-treated high-risk adults with elevated triglycerides
formulation-specific randomized trials
Released bottom line
Two mixed EPA+DHA trials were neutral on primary outcomes; prescription icosapent ethyl benefited a defined high-risk population with safety and comparator limits.
What this does not establish
“Omega-3” is not one intervention—and the trial results do not transfer
Checked
meal timing · weight, body composition, visceral fat and cardiometabolic markers
Methods guidance with bounded examples from two human randomized trials
Population or modelCurrent trial-reporting guidance illustrated with a four-week pectin pilot and the long-running ACTIVE cognitive-training trial
methods synthesis with two bounded randomized-trial examples
Released bottom line
Outcome labels are a map of the trial's questions, not a truth score; multiplicity, interaction tests, analysis populations, effect size, uncertainty and replication remain separate checks.
What this does not establish
The explainer does not establish that pectin or cognitive training improves health, prevents dementia, extends life or merits a treatment recommendation.
Source status checked
wheat-germ spermidine extract · memory and cognitive tests
Population or modelOlder adults with subjective cognitive decline
small randomized phase 2b trial
Released bottom line
In the 12-month SmartAge trial, a wheat-germ spermidine extract did not improve the prespecified memory outcome or secondary outcomes. Exploratory signals do not establish dementia prevention or longer life.
What this does not establish
Spermidine did not improve the trial’s primary memory outcome
Checked
shingles vaccine · herpes-zoster disease and recorded dementia diagnoses
Human disease outcomes · randomized and non-randomized evidence
Population or modelAdults age 50 or older in ZOE-50 plus older vaccine-eligible cohorts in two dementia analyses
randomized and non-randomized evidence
Released bottom line
Randomized trials established shingles prevention. Dementia findings come from observational and quasi-experimental studies and do not prove prevention.
Human cognitive tests · randomized multidomain trial
Population or model1,260 Finnish adults age 60–77 at elevated dementia risk and with average-to-lower cognitive performance
randomized multidomain trial
Released bottom line
A combined two-year program produced a small cognitive-test advantage; it cannot identify a winning component or establish dementia, disability, mortality, healthspan, or lifespan benefit.
What this does not establish
FINGER slightly improved cognitive-test scores. It did not prove dementia prevention
Checked
MIND diet · global cognition and structural MRI measures
Human cognition and MRI · randomized dietary trial
Population or model604 adults age 65 or older without cognitive impairment, with family dementia history, overweight and a suboptimal diet
randomized dietary trial
Released bottom line
Both groups improved with counseling and calorie restriction; the between-group cognitive difference was not significant and MRI measures were similar.
What this does not establish
The MIND diet trial found no cognitive edge over its active control
Checked
cognitive training · trained abilities, daily function, all-cause mortality and claims-diagnosed dementia
Human trained abilities and long-term outcomes · randomized trial plus disputed secondary analysis
Population or model2,832 independent U.S. adults age 65–94
randomized trial plus disputed secondary analysis
Released bottom line
ACTIVE supports trained-ability gains and some function signals, found no mortality benefit, and leaves a claims-based dementia subgroup methodologically disputed.
What this does not establish
Cognitive training improved practiced skills—not survival or proven dementia prevention
Checked
multivitamins · cognitive-test scores, word recall and DNA-methylation biomarkers
Human cognitive tests and biomarkers · correlated randomized substudies
Population or modelOlder adults in related telephone, web, clinic and blood-based COSMOS substudies
correlated randomized substudies
Released bottom line
COSMOS found small cognitive-test differences and modest movement in two DNA-methylation clocks; neither establishes dementia prevention or longer life.
What this does not establish
Multivitamins moved some tests and aging clocks. What does that mean?
Checked
resveratrol · memory tests, metabolic markers, body composition, inflammation and exercise adaptation
Human biomarkers and function · small 24-week randomized trial
Population or model62 selected healthy Japanese adults age 65 or older randomized at one center; 60 entered the authors' efficacy analysis and 58 completed 24 weeks
double-blind randomized trial; 1,250 mg/day oral NMN versus matched placebo for 24 weeks
Released bottom line
Whole-blood NAD rose markedly, while the registered hearing outcome and measured physical function did not show attributable improvement.
What this does not establish
The trial did not establish slower aging, tissue rejuvenation, disease prevention, healthspan or lifespan benefit, long-term safety or a supplement recommendation.
Source status checked
reduced dietary protein · fasting autophagic flux in circulating immune cells
Human biomarkers and health associations · multimodal model-development study
Population or modelSex-stratified MRI, proteomic and metabolomic models using MULTI cohorts, with downstream UK Biobank, BLSA, ADNI and A4 analyses
age-prediction model development and internal holdouts, followed by observational, genetic and secondary trial-data analyses
Released bottom line
Sex-stratified models exposed different patterns, but mixed performance and absent external validation keep them research tools rather than clinical tests.
What this does not establish
The study did not establish diagnosis, individual prognosis, a validated surrogate endpoint, treatment response, slower aging, healthspan or lifespan.
Checked
rentosertib · predicted-age change from six protein-based aging clocks
Human biomarkers · exploratory ancillary trial analysis
Population or model42 adults with idiopathic pulmonary fibrosis who consented and had complete four-timepoint serum samples from a 71-person randomized phase 2a trial
exploratory ancillary analysis across three rentosertib regimens and placebo over 12 weeks
Released bottom line
Twenty-one of 54 regimen–time–clock comparisons met the authors’ Q<0.10 threshold, concentrated at week 4.
What this does not establish
The analysis did not establish clinical benefit, slower aging, healthspan, lifespan, healthy-person benefit or a validated surrogate endpoint.
Checked
CT-derived biological-age model · chronological-age prediction, prevalent disease, incident disease and discrimination
Human biomarkers and disease associations · single-center observational study
Population or model7,837 adults from one University of Tokyo health-screening cohort, including 3,174 initially disease-free people followed a median 6.5 years
same-source model development, prevalent-disease testing and longitudinal observational testing; CT age gap compared with chronological age
Released bottom line
Each 1-SD higher CT age gap was associated with prevalent disease (OR 1.35) and incident disease (HR 1.24); five-year tAUC was 0.700 versus 0.688 for chronological age.
What this does not establish
The study did not establish causation, external validity, clinical utility, diagnosis, prevention benefit, slower aging or a reason to obtain CT imaging.
Human biomarkers and function · very small randomized trial
Population or modelVery small sample of older adults
very small randomized trial
Released bottom line
A 16-week study randomized 24 older adults—12 per arm—and reported many biomarker and function measures. Its size, multiplicity and exploratory analyses do not prove that GlyNAC reverses aging or extends healthspan.
What this does not establish
GlyNAC’s small trial cannot establish reversal of aging
Checked
habitual winter swimming and cold challenge · brown-fat activity and thermogenesis
Human physiology biomarkers · small cross-sectional study
Population or modelVery small selected sample of young healthy men
cross-sectional swimmer versus matched comparison group
Released bottom line
A small study of young male winter swimmers found physiology differences. It did not test disease, function, healthspan or lifespan, and it cannot show that cold exposure caused the findings.
What this does not establish
Cold-water studies measure thermogenesis—not longer life
Checked
supervised hyperbaric-oxygen research program · selected blood-cell telomere and senescence markers
Human blood-cell biomarkers · uncontrolled pre/post study
Population or modelSmall selected group of healthy adults age 64 or older
single-arm pre/post study without a control
Released bottom line
A small uncontrolled study reported telomere and senescent-cell changes in selected blood-cell subtypes. It did not test clinical aging, healthspan or lifespan, and commercial conflicts matter.
Population or model1.48 million adults age 20–79 in four national cohorts, with a separate 202,248-person US linked-cohort analysis
observational current and former cigarette smokers compared with never smokers; cessation timing compared with continued smoking
Released bottom line
Current cigarette smoking was associated with roughly three times the mortality of never smoking; stopping was associated with lower excess mortality at every age studied.
What this does not establish
The analyses did not establish an exact causal effect for every subgroup, forecast an individual lifespan, or compare cessation treatments.
Checked
intensive multi-drug glycemia strategy targeting HbA1c below 6% · major cardiovascular events, all-cause mortality and treatment harms
Human cardiovascular events, mortality and safety · large randomized trial
Population or model10,251 adults with established type 2 diabetes and high cardiovascular risk
intensive glycemia target below 6% versus standard target of 7.0% to 7.9%
Released bottom line
The primary cardiovascular outcome was not significantly lower (352 versus 371 events; hazard ratio 0.90; P=0.16). Deaths were higher with intensive treatment (257 versus 203; hazard ratio 1.22; P=0.04), prompting early discontinuation.
What this does not establish
ACCORD does not show that all glucose lowering is harmful; it tested one intensive, multi-drug target strategy in a high-risk population.
Checked
invitation to one colonoscopy · colorectal-cancer incidence and mortality
Human cancer incidence and mortality · large randomized invitation trial
Population or modelAdults age 55–64 in Norway, Poland and Sweden
randomized invitation versus usual care
Released bottom line
At 13 years, colorectal cancer was diagnosed in 1.46% of the invited group and 1.80% of the usual-care group. Colorectal-cancer mortality was 0.41% versus 0.47%; the confidence interval included no difference.
What this does not establish
A colorectal-cancer mortality or all-cause survival benefit was not demonstrated.
Checked
three annual low-dose CT screens · lung-cancer and all-cause mortality
Human lung-cancer mortality · large randomized screening trial
Population or modelSelected current and former heavy smokers age 55–74
randomized low-dose CT versus chest radiography
Released bottom line
The original NLST analysis reported 247 versus 309 lung-cancer deaths per 100,000 person-years, a 20% relative reduction with low-dose CT. It did not test never-smokers or the general population.
What this does not establish
Benefit for never-smokers, average-risk adults or overall lifespan.
Checked
repeated PSA-based screening · prostate-cancer mortality, metastasis and diagnoses
Human prostate-cancer mortality and diagnosis · long randomized screening follow-up
Population or modelMen age 55–74 in Rotterdam; primary group age 55–69
randomized screening invitation versus usual care
Released bottom line
In the primary age group, prostate-cancer mortality was lower with screening (RR 0.73), as was metastatic disease (RR 0.67). Screening also produced 57 excess prostate-cancer diagnoses per 1,000 men randomized.
What this does not establish
An all-cause survival benefit or favorable balance for every individual.
Checked
habitual sauna use · cardiovascular and all-cause mortality association
One Finnish male cohort linked frequent sauna use with lower mortality. The design cannot show that sauna caused longer life, and randomized evidence has not tested that endpoint.
What this does not establish
Sauna use was associated with lower mortality—not proven to extend life
Checked
low-dose aspirin · cancer mortality · long-term follow-up
Human mortality and cancer outcomes · randomized trial plus observational extension
Population or model19,114 original ASPREE participants; 14,907 cancer-free survivors in the post-trial analysis
randomized trial plus observational extension
Released bottom line
The randomized trial found an unexpected cancer-mortality imbalance. Longer follow-up found no difference in overall cancer incidence and no post-trial mortality legacy effect.
What this does not establish
ASPREE’s cancer signal changed across longer follow-up
Checked
Method
One released story, one primary group.
All 66 canonical stories appear exactly once. A story may expose several measured-result filters, but it is never duplicated. Open the full article for sources, endpoints, limitations, funding, conflicts, safety context and corrections.
Follow an intervention across reporting, studies and trials
These pages connect only exact identities already present in released coverage. Counts and order are not evidence strength, efficacy, safety, importance, popularity or recommendation.